falsefalse

My Treatment Approach: Metastatic Castration-Resistant Prostate Cancer - Episode 9

Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC

,

Drs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: The Evolution of Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    EP. 2: Approved Treatment Options for Patients with mCRPC
    EP. 3: Patient Profile: A 78-Year-Old Man with mCRPC
    EP. 4: Treatment Approaches for Patients with mCRPC and Bone-Only Disease Progression After Radiotherapy
    EP. 5: Patient Profile: A 72-Year-Old Man with mCRPC and Multiple Bone Metastases
    EP. 6: Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC
    EP. 7: Considerations for Treatment Selection for Patients with Disease Progression on Radium-223
    EP. 8: Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases
    Now Viewing
    EP. 9: Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC
    EP. 10: Closing Thoughts on the Future of mCRPC Treatment

    Related Content:

    My Treatment Approach: Metastatic Castration-Resistant Prostate CancerProstate CancerInsights
    Five Under 5: Top Oncology Videos for the Week of 3/30
    Future Considerations for Treatment Sequencing in B-ALL
    Treatment Sequencing Decisions for B-ALL: Perspectives From Moffitt Cancer Center
    x